LUMZURALI
Live / Applied — Third extension granted (statement of use) (as of 24 Jul 2025)
What this means for you
Not registered yet, but its 08 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97828313
- Mark type
- Stylized text
- Filed
- 08 Mar 2023
- Published for opposition
- 09 Jan 2024
- Attorney of record
- Steven A. Abreu
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of central nervous system diseases and disorders, depression, anxiety disorder, and bipolar depression
Owner
- Sage Therapeutics, Inc., Cambridge, MA, US
- Sage Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 25 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jul 2025 — SOU EXTENSION 3 GRANTED
- 24 Jul 2025 — SOU EXTENSION 3 FILED
- 24 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 26 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Feb 2025 — SOU EXTENSION 2 GRANTED
- 25 Feb 2025 — SOU EXTENSION 2 FILED
- 25 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 14 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 Aug 2024 — SOU EXTENSION 1 GRANTED
- 14 Aug 2024 — SOU EXTENSION 1 FILED
- 14 Aug 2024 — SOU TEAS EXTENSION RECEIVED
- 05 Mar 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 09 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jan 2024 — PUBLISHED FOR OPPOSITION